RxDoctor Payments Data

Fernando Fuentes, MD

Critical Care Medicine · Reno, NVNPI 1952669640

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,164 of the $4,131 with a category attached, or 76.6%. Olympus Corporation Of The Americas accounts for 78.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,930, more than ten times the $161 reported in 2019. Among critical care medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,131in general payments, 2019–2025

Across 42 payments — averaging $98.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$3K
  • United Therapeutics Corporation$289
  • GSK$232
  • Genentech USA, Inc.$140
  • Boehringer Ingelheim$136
  • Regeneron Healthcare Solutions, Inc.$64
  • plus $22 from 1 others

What the payments were for

  • Travel & lodging$3,16477%
  • Food & beverage$96823%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,131 in reported general payments places this provider in the 90th percentile of 68 critical care medicine providers in Nevada.

See all critical care medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$17,900
Medicare patients
112
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide24$14,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$14,357
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,430
DuleraMometasone/Formoterol11$4,711
SymbicortBudesonide/Formoterol Fumarate17$3,862
BreynaBudesonide/Formoterol Fumarate13$2,374
Albuterol Sulfate HfaAlbuterol Sulfate28$1,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$232$25,78734 claims
Boehringer IngelheimSpiriva Respimat$136$14,97124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 critical care medicine providers in Nevada.

Other critical care medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →